Reata to Present Promising Results on Bardoxolone Methyl in Treating Alport, Other Kidney Diseases
Reata Pharmaceuticals will present promising data of its investigational therapy bardoxolone methyl in the treatment of rare forms of chronic kidney disease, including Alport syndrome, the company announced. Results of two Phase 2 clinical trials will be presented through four scientific posters during the annual American Society of…